Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875176 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL29870420 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL26299278 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661478 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661021 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL851826 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661377 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL101673 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL6555279 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL16559904 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4612196-A1 | GRAFTABLE BIOCIDAL LINKERS AND POLYMERS AND USES THEREOF | Debogy Molecular, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250214954-A1 | METHODS OF TREATING HIV USING TRITERPENE DERIVATIVES | HETERO LABS LIMITED (IN) | 2025-07-03 | — | — | US | disclosed |
| US-12275712-B2 | Triterpene derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2025-04-15 | — | — | US | disclosed |
| EP-4504694-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | Capstan Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-3824325-B1 | VEHICLE SENSORS COMPRISING REPELLENT SURFACE, PROTECTIVE FILMS, REPELLENT COATING COMPOSITIONS, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240299311-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-12023661-B2 | Nitrogen heterocyclic carbene ligands and ruthenium catalysts thereof, preparation method therefor and application thereof | Paimai New Materials (chengdu) Co., Ltd. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-20030027748-A1 | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | BIOCON LIMITED (IN) | 2003-02-06 | — | — | US | disclosed |
| US-20030027995-A1 | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | BIOCON LIMITED (IN) | 2003-02-06 | — | — | US | disclosed |
| WO-2002098446-A1 | MIXTURES OF DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME | NOBEX CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002098452-A1 | MIXTURES OF GROWTH HORMONE DRUG-OLIGOMER CONJUGATES COMPROMISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME | NOBEX CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-2001034573-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2001-05-17 | — | — | WO | disclosed |
| US-5492687-A | X-RAY CONTRAST AGENTS | STERLING WINTHROP INC. (US) | 1996-02-20 | — | — | US | disclosed |
| US-5466435-A | X-ray contrast agents, radiology | STERLING WINTHROP INC. (US) | 1995-11-14 | — | — | US | disclosed |
| EP-0619121-A2 | Compositions of iodophenoxy alkylene ethers for visualization of the gastrointestinal tract | NYCOMED IMAGING AS (NO) | 1994-10-12 | — | — | EP | disclosed |
| US-5348727-A | Diagnostics | STERLING WINTHROP INC. (US) | 1994-09-20 | — | — | US | disclosed |
| EP-0614670-A2 | Compositions of iodophenoxy alkylene ethers in film-formin materials for visualization of the gastrointestinal tract | NYCOMED IMAGING AS (NO) | 1994-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | USP2 2815/4885TSHR 1846/4885KDM4E 1725/4885 |
| US-20030027748-A1 | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | IAPP, SI, IDE | USP2 2083/4885TSHR 1412/4885KDM4E 4615/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | USP2 2815/4885TSHR 1846/4885KDM4E 1725/4885 |
| US-12275712-B2 | Triterpene derivatives as HIV inhibitors | CCR5, CYP51A1, CYP4A11 | USP2 4552/4885TSHR 3231/4885KDM4E 1058/4885 |
| US-20240299311-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | USP2 4861/4885TSHR 894/4885KDM4E 4434/4885 |
| US-20030027995-A1 | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | GHRHR, GHSR, GHITM | USP2 774/4885TSHR 43/4885KDM4E 4494/4885 |
| US-20250214954-A1 | METHODS OF TREATING HIV USING TRITERPENE DERIVATIVES | CCR5, HSD17B7, CYP51A1 | USP2 4605/4885TSHR 3125/4885KDM4E 1708/4885 |
| US-12023661-B2 | Nitrogen heterocyclic carbene ligands and ruthenium catalysts thereof, preparation method therefor and application thereof | WEE2, WEE1, FARSB | USP2 3586/4885TSHR 4011/4885KDM4E 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.